Partnerships, Licensing, Investments and M&A Deals and Trends for January 2015 in Pharmaceuticals

Pages: 65 Published: March 02, 2015 Report Code: GDPH0474MD

  • Overview
  • Contents
  • Tables
  • Figures
  • Listen
    Text to Speech Demo

"GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for January 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in January 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry. Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research."

Scope

"• Analysis of the market trends for the pharmaceutical industry in the global arena.

• Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

• Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

• Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

• Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

• Analysis of partnership and licensing deals based on clinical stage of development of products.

• Summary of the pharmaceutical deals globally in the six months.

• Information on the top deals happened in the pharmaceutical industry.

• Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

• League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs."

Reasons to Buy

"• Enhance your decision making capability in a more rapid and time sensitive manner.

• Find out the major deal performing segments for investments in your industry.

• Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

• Identify companies that are aggressively looking to raise capital in the market

• Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

• Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

• Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

• Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

• Identify growth segments and opportunities in each region within the industry.

• Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry."

Table of Contents

"1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 7

1.2 List of Figures 10

2 Pharmaceuticals & Healthcare, Global, Deal Summary 13

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, January 2015 13

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, January 2015 15

2.2.1 LabCorp Raises USD2.9 Billion in Public Offering Notes 15

2.2.2 AmerisourceBergen Acquires MWI Veterinary Supply for USD2.45 Billion 15

2.2.3 Hubei Biocause Pharma Raises USD1.6 Billion in Private Placement of Shares 17

2.2.4 Torrent Pharma Plans Private Placement of Bonds for USD1.22 Billion 17

2.2.5 Endo International Prices Private Placement of 6% Notes Due 2014 for USD1.2 Billion 17

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, January 2015 18

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, January 2015 19

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20

3.1 Pharmaceuticals & Healthcare, Global, M&A, December 2014 20

3.1.1 Top M&A Deals in January 2015 21

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, August 2014 – January 2015 22

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, January 2015 24

3.2.1 Top Equity Offering Deals in January 2015 25

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, August 2014 – January 2015 26

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, January 2015 27

3.3.1 Top PE/VC Deals in January 2015 28

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, January 2015 29

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, January 2015 30

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, August 2014–January 2015 32

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2014–January 2015 33

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, January 2015 34

4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, January 2015 34

4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, August 2014 – January 2015 36

4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), January 2015 37

4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, January 2015 38

4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), August 2014 – January 2015 39

4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, August 2014 – January 2015 41

4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), August 2014 – January 2015 42

4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2014 – January 2015 44

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, January 2015 46

5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, January 2015 46

5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), January 2015 48

5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, January 2015 49

5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, January 2015 50

5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, January 2015 50

5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), August 2014 – January 2015 51

5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), August 2014 – January 2015 52

5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), August 2014 – January 2015 54

5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), August 2014 – January 2015 56

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 58

6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, January 2015 58

6.1.1 Oncology – Deals of the Month 59

6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, January 2015 63

6.2.1 Central Nervous System – Deals of the Month 64

6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, January 2015 66

6.3.1 Infectious Diseases – Deals of the Month 68

6.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, January 2015 70

6.4.1 Cardiovascular – Deals of the Month 71

6.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, January 2015 73

6.5.1 Immunology – Deal of the Month 74

6.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, January 2015 76

6.6.1 Gastrointestinal – Deals of the Month 77

6.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, January 2015 79

6.7.1 Metabolic Disorders – Deal of the Month 80

7 Deal Summary by Geography 82

7.1 Pharmaceuticals & Healthcare, North America Deals, January 2015 82

7.1.1 North America – Deals of the Month 83

7.2 Pharmaceuticals & Healthcare, Europe, Deals, January 2015 87

7.2.1 Europe – Deals of the Month 88

7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, January 2015 90

7.3.1 Asia-Pacific – Deals of the Month 91

7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, January 2015 93

7.4.1 Rest of the World – Deals of the Month 94

8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 95

8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, August 2014 – January 2015 95

8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, August 2014 – January 2015 97

9 Further Information 99

9.1 Methodology 99

9.2 About GlobalData 100

9.3 Disclosure information 101

9.4 Disclaimer 101

"

List of Tables

"1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 14

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, December 2014 15

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), January 2015 19

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 21

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, January 2015 21

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2014 – January 2015 23

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 25

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, January 2015 25

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 26

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 28

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, January 2015 28

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, August 2014 – January 2015 30

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), January 2015 31

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 32

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2014 – January 2015 33

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 35

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 36

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2014 – January 2015 37

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), January 2015 38

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2014 – January 2015 40

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2014 – January 2015 43

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), August 2014 – January 2015 45

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 47

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), August 2014 – January 2015 49

Table 25: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, January 2015 49

Table 26: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, January 2015 50

Table 27: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, January 2015 50

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 51

Table 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), January 2015 53

Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2014 – January 2015 55

Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), January 2015 57

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 59

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 64

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 67

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 71

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 74

Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 77

Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 80

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 83

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 88

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 91

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 94

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 96

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 98

"

List of Figures

"1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 13

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%),January 2015 18

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), January 2015 19

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 20

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2014 – January 2015 22

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 24

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 26

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 27

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2014 – January 2015 29

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), January 2015 30

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), January 2015 31

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 32

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 34

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 36

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2014 – January 2015 37

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2014 – January 2015 39

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2014 – January 2015 41

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2014 – January 2015 42

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2014 – January 2015 44

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 46

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2014 – January 2015 48

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 51

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2014 – January 2015 52

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, August 2014 – January 2015 54

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), August 2014 – January 2015 55

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), January 2015 56

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 58

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 63

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 66

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 70

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 73

Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 76

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 79

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 82

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 87

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 90

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 93

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 95

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2014 – January 2015 97

"

$1000

Can be used by individual purchaser only

$3000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.